Pharmaceutical composition and application thereof in preparation of drugs for treating targeted calreticulin mutation type myeloproliferative diseases

A technology for bone marrow proliferation and calreticulin, applied in the field of biomedicine, can solve the problems of patient recurrence and inability to eradicate mutant cells.
CN112843055AActive Publication Date: 2021-05-28XUZHOU MEDICAL UNIV
1 Cites 2 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
XUZHOU MEDICAL UNIV
Publication Date
2021-05-28

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a pharmaceutical composition and an application thereof in preparation of drugs for treating targeted calreticulin mutation type myeloproliferative diseases, wherein the pharmaceutical composition is composed of MK-2206 and AZD 6244; CALR gene mutation type MARMO cells are adopted as research objects (the cells are specific unresponsive cells of rucotinib), a double-drug combination method capable of being applied to targeted CALR mutation type myeloproliferative diseases is explored, and a basis is provided for clinical drug combination treatment of patients who do not respond to rucotinib.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a pharmaceutical composition and its application in the preparation of drugs for treating myeloproliferative diseases targeting calreticulin mutation types. Background technique

[0002] Myeloproliferative neoplasms (Myeloproliferative Neoplasms, MPNs) are a group of malignant clonal diseases originating from hematopoietic stem cells, which are specifically manifested as hyperplasia of one or more lines of myeloid cells and increased counts of white blood cells and red blood cells in peripheral blood, but the cell morphology is relatively normal. Usually accompanied by liver, spleen and lymphadenopathy. According to different clinical manifestations, the disease can be divided into polycythemia vera (PV), essential thrombocythemia (Essential Thrombocythemia, ET) and primary myelofibrosis (Primary Myelofibrosis, PMF). Existing studies have shown that driver gene mu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More